| Literature DB >> 34853070 |
Gina Bouchard1,2,3, Fernando Jose Garcia-Marques2, Loukia Georgiou Karacosta1, Weiruo Zhang1, Abel Bermudez2, Nicholas McIlvain Riley4, Sushama Varma5, Lindsey Catherine Mehl1, Jalen Anthony Benson6, Joseph B Shrager6, Carolyn Ruth Bertozzi4, Sharon J Pitteri2, Amato J Giaccia3,7, Sylvia Katina Plevritis1,2.
Abstract
The invasive leading edge represents a potential gateway for tumor metastasis. The role of fibroblasts from the tumor edge in promoting cancer invasion and metastasis has not been comprehensively elucidated. We hypothesize that cross-talk between tumor and stromal cells within the tumor microenvironment results in activation of key biological pathways depending on their position in the tumor (edge vs. core). Here we highlight phenotypic differences between tumor-adjacent-fibroblasts (TAF) from the invasive edge and tumor core fibroblasts from the tumor core, established from human lung adenocarcinomas. A multiomics approach that includes genomics, proteomics, and O-glycoproteomics was used to characterize cross-talk between TAFs and cancer cells. These analyses showed that O-glycosylation, an essential posttranslational modification resulting from sugar metabolism, alters key biological pathways including the cyclin-dependent kinase 4 (CDK4) and phosphorylated retinoblastoma protein axis in the stroma and indirectly modulates proinvasive features of cancer cells. In summary, the O-glycoproteome represents a new consideration for important biological processes involved in tumor-stroma cross-talk and a potential avenue to improve the anticancer efficacy of CDK4 inhibitors. SIGNIFICANCE: A multiomics analysis of spatially distinct fibroblasts establishes the importance of the stromal O-glycoproteome in tumor-stroma interactions at the leading edge and provides potential strategies to improve cancer treatment. See related commentary by De Wever, p. 537. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2022 PMID: 34853070 PMCID: PMC9075699 DOI: 10.1158/0008-5472.CAN-21-1705
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312